Literature DB >> 17338886

[Intramural aortic hematoma and anticoagulation].

María Victoria Cañadas1, Isidre Vilacosta, Joaquín Ferreirós, Ana Bustos, Joaquín Díaz-Mediavilla, Enrique Rodríguez.   

Abstract

Intramural aortic hematoma is one of a group of conditions covered by the term acute aortic syndrome. Many aspects of its natural history remain poorly understood, and the best treatment is not known. The aim of this study was to describe the clinical and radiological characteristics and follow-up of a group of patients with intramural aortic hematoma who received anticoagulant therapy during hospitalization. We selected a prospective cohort of patients with a diagnosis of intramural aortic hematoma and carried out an analysis of those who received anticoagulation treatment during the acute phase of the illness. Patients received anticoagulation for a range of different reasons. In all patients, the intramural aortic hematoma was observed to undergo gradual regression despite anticoagulation therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17338886

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  3 in total

Review 1.  Acute Aortic Syndromes: Update in Current Medical Management.

Authors:  Jacqueline H Morris; Doran Mix; Scott J Cameron
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-04

2.  Aortic intramural hematoma after thrombolysis in a patient with acute massive pulmonary embolism.

Authors:  Min Su Kim; Kyu Seop Kim; Il Soon Jung; Jae-Hyeong Park; Jin-Ok Jeong; Si Wan Choi; In-Whan Seong
Journal:  Korean J Intern Med       Date:  2013-08-14       Impact factor: 2.884

3.  Anticoagulant and anti-thrombotic therapy in acute type B aortic dissection: when real-life scenarios face the shadows of the evidence-based medicine.

Authors:  Pier Paolo Bocchino; Ovidio De Filippo; Francesco Piroli; Paolo Scacciatella; Massimo Imazio; Fabrizio D'Ascenzo; Gaetano Maria De Ferrari
Journal:  BMC Cardiovasc Disord       Date:  2020-01-23       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.